Close MenuClose
Close Menu
Tal Teitz, PhD

Associate Professor

Pharmacology & Neuroscience

Tal Teitz

Contact

School of Medicine
Pharmacology and Neuroscience
Graduate School
Neuroscience (Master of Science)
CRISS III - Criss 3

Tal Teitz, PhD

Associate Professor

Pharmacology & Neuroscience



Curriculum Vitae

Research Focus

- Therapeutic intervention for chemotherapy-induced, noise-induced and age-related hearing
   loss.
- Function and protection of sensory cells in the mouse cochlea.
- Repurposing FDA-approved drugs for hearing loss and acute kidney injury caused by 
  cisplatin chemotherapy.

Department

Pharmacology and Neuroscience

Position

Associate Professor

Articles

  • Science Advances
    Teitz T.- senior author, BRAF Inhibition Protects Against Hearing Loss in Mice. Science Advances, 2020, Dec 2;6(49):eabd0561. doi: 10.1126/sciadv.abd0561. PMID:33268358.
    6(49), p. eabd0561 2020
  • Journal of Medicinal Chemistry
    AbstractThere are currently no FDA-approved therapies to prevent the hearing loss associated with the usage of cisplatin in chemotherapeutic regimens. We recently demonstrated that the pharmacologic inhibition with kenpaullone or genetic deletion of CDK2 preserved hearing function in animal models treated with cisplatin, which suggests that CDK2 is a promising therapeutic target to prevent cisplatin-induced ototoxicity. In this study, we identified two lead compounds, AT7519 and AZD5438, from a focused library screen of 187 CDK2 inhibitors, performed in an immortalized cell line derived from neonatal mouse cochleae treated with cisplatin. Moreover, we screened 36 analogues of AT7519 and identified analogue 7, which exhibited an improved therapeutic index. When delivered locally, analogue 7 and AZD5438 both provided significant protection against cisplatin-induced ototoxicity in mice. Thus, we have identified two additional compounds that prevent cisplatin-induced ototoxicity in vivo and provided further evidence that CDK2 is a druggable target for treating cisplatin-induced ototoxicity.
    volume 61(17), p. 7700-7709 2018

Publications

  • ARO annual Meeting
    Teitz T.- senior author/ Lutze R.- First Author, Richard Lutze, Matthew Ingersoll, Daniel Kresock, Emma Malloy, Tal Teitz 'Erk 1/2 Inhibitor AZD-0364 Mitigates Noise-Induced Hearing Loss in Mice.' 2022
  • ARO annual Meeting
    Tal Teitz- Senior Author, Daniel Kresock- First Author, Daniel Kresock, Matthew Ingersoll, Richard Lutze, Chithra Pushpan, Jordan Marsh, Tal Teitz Knockout of KSR1 Gene and BRAF Inhibitor Dabrafenib Protect Against Noise Induced Hearing Loss 2022
  • ARO annual Meeting
    Teitz T.- senior author/ Pushpan C.- First Author, Chithra Pushpan, Daniel Kresock, Matthew Ingersoll, Darby Keirns, William Hunter, Khalid Bashir, Tal Teitz 'CDK2 Inhibitor AZD5438 Protects From Cisplatin-Induced Acute Kidney Injury and Hearing Loss.' 2022
  • ARO annual Meeting
    Tal Teitz senior author, Matthew Ingersoll- First Author, Matthew Ingersoll, Richard Lutze, Daniel Kresock, Duane Currier, Taosheng Chen, Jian Zuo, Tal Teitz Presented a talk and Poster on the scientific work in the Annual Association Meeting: Tamiflu as a Therapeutic Candidate for Noise-Induced Hearing Loss. 2022
  • ARO annual Meeting
    Teitz T.- senior author/ Ingersoll M.- First Author, Matthew Ingersoll, Daniel Kresock, Richard Lutze, Jordan Marsh, Chithra Pushpan, Tal Teitz 'Deletion of the KSR1 Gene Validates the Role of the MAPK Pathway in the Mechanism of Cisplatin Induced Hearing Loss.' 2022
  • ARO annual Meeting
    Teitz T.- senior author/ Darby Keirns - First Author, Darby Keirns, Chithra Pushpan, Daniel Kresock, Matthew Ingersoll, William Hunter, Khalid Bashir, Tal Teitz 'Dual Effect: BRAF Inhibitor Dabrafenib Protects Against Cisplatin-Induced Kidney Injury and Hearing Loss.' 2022
  • Teitz T.- senior author, Ingersoll MA, Lutze R, Kresock DF, Malloy A, Caster LE, Holland E, Teitz T. Repurposing FDA-approved MEK inhibitor Trametinib for protection from cisplatin-induced hearing loss. June 3rd and 4th, 2021 Bellucci Symposia on Drug Therapeutics for Hearing Loss, Translational Hearing Center and Creighton University’s School of Medicine, Omaha, NE, USA. 2021
  • Teitz T.- senior author, Pushpan CK, Kresock DF, Ingersoll MA, Keirns DL, Hunter WJ, Bashir K, Teitz T. CDK2 inhibitor AZD5438, a dual candidate therapeutic for cisplatin-induced kidney injury and hearing loss. June 3rd and 4th, 2021, Bellucci Symposia on Drug Therapeutics for Hearing Loss, Translational Hearing Center and Creighton University’s School of Medicine, Omaha, NE, USA. 2021
  • Teitz T.- senior author, Lutze RD, Ingersoll MA, Kresock DF, Malloy EA, Caster LE, Holland EM, Teitz T. ERK1/2 inhibitor AZD-0364 Protects from Noise-Induced Hearing Loss. June 3rd and 4th, 2021, Bellucci Symposia on Drug Therapeutics for Hearing Loss, Translational Hearing Center and Creighton University’s School of Medicine, Omaha, NE, USA. 2021
  • Teitz T.- Senior Author, Malloy EA*, Ingersoll MA, Caster LE, Holland EM, Xu Z, Zallocchi M, Currier D, Liu H, He D.Z.Z., Min J, Chen T, Zuo J, Teitz T. Dabrafenib prevents cisplatin-induced hearing loss in mice. Medical Students Poster Session, 2021, Creighton University, Omaha, NE, USA. (*First Place Poster). 2021
  • Assoc. Res. Otolaryngol
    Teitz T.- senior author, Caster LE, Ingersoll MA, Holland EM, Malloy EA, Currier D, Min J, Chen T, Zuo J, Teitz T. Investigation of small-molecule B-RAF inhibitors for protection of cochlear hair cells from cisplatin toxicity. College of Arts & Science Deans Summer Research Fellowship, Center for Undergraduate Research and Scholarship (CURAS), 2019, Creighton University, Omaha, NE, USA. 2020
  • Assoc. Res. Otolaryngol
    Teitz T. -senior author, Caster LE, Ingersoll MA, Holland EM, Malloy EA, Currier D, Min J, Chen T, Zuo J, Teitz T. Investigation of small-molecule B-RAF inhibitors for protection of cochlear hair cells from cisplatin toxicity. Association for Research in Otolaryngology (ARO) 43rd Annual Midwinter Meeting 2020, San Jose, CA., USA. 2020
  • ARO annual Meeting
    Teitz T.- senior author, Ingersoll MA, Caster LE, Holland EM, Malloy EA, Xu Z, Feng H, Currier D, Min J, Chen T, Zuo J, Teitz T. Repurposing an FDA approved Drug Dabrafenib for Protection from Noise- and Cisplatin-Induced Hearing Loss. Association for Research in Otolaryngology (ARO) 43rd Annual Midwinter Meeting 2020, Podium # 146, San Jose, CA., USA. 2020
  • Assoc. Res. Otolaryngol
    Salehi P., Gene expression and pathway analysis of cisplatin-treated cochlear cells. Association for Research in Otolaryngology (ARO) 42nd Annual Midwinter Meeting 2019, Poster # 199, Baltimore, MD., USA. 2019
  • ARO annual Meeting
    Teitz T. et al., Abstract for Meeting: Development of Small Molecule Protein Kinase Inhibitors for Hearing Protection (last author)
    42nd ARO Annual Meeting, p. 44 2019
  • Assoc. Res. Otolaryngol
    Li Z. et al., Molecular simulations of CDK2 inhibitors that prevent ototoxicity effect of cisplatin. Association for Research in Otolaryngology (ARO) 42nd Annual Midwinter Meeting 2019, Poster # 466, Baltimore, MD., USA. 2019
  • ARO annual Meeting
    Teitz T.- senior author, Ingersoll MA, DiGuiseppi J, Caster LE, Xu Z, Currier D, Zallochi ML, Min J, Chen T, Zuo J, Teitz T. Development of Small-Molecule Protein Kinase Inhibitors for Hearing Protection. Association for Research in Otolaryngology (ARO) 42nd Annual Midwinter Meeting 2019, Podium # 26, Baltimore, MD., USA. 2019

Presentations

  • Bellucci 2022 Symposium on Aging and Age-related Hearing Loss-'Dabrafenib, a BRAF Inhibitor Protects Against Cisplatin-Induced Kidney Injury and Hearing Loss.' 2022
  • Bellucci Symposia 2022- ''Repurposing Oseltamivir to Prevent Noise-induced hearing Loss.' Regina Kelmann and Emma Sailor First co-authors. 2022
  • Bellucci Symposium 2022- 'Repurposing FDA-approved MEK Inhibitor Trametanib for Protection from Cisplatin Induced Hearing Loss.' 2022
  • Bellucci Symposia 2022- Aging and Age-related Hearing Loss. 'ERK 1/2 Inhibitor Protects from Noise-induced Hearing Loss.' 2022
  • Tamiflu as a Therapeutic Candidate for Noise-Induced Hearing Loss- ARO Meeting 2022. 2022
  • “Development of New Pharmacologic Agents for Hearing Loss and Vestibular Pathology”. Center for Comparative Evolutionary Biology of Hearing, Translational Research Day, University of Maryland, College Park, School of Medicine, Baltimore, MD, Dec 9, 2021. 2021
  • Gave a presentation in the 5th Chinese Hearing Research Conference on our research studies , Beijing, China 2019, titled "Drug Development for Cisplatin- and Noise- induced Hearing Loss." 2019
  • Research Rounds and Seminars at Department of Pharmacology and Neuroscience 2019